High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.
Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
Moby summary of Vertex Pharmaceuticals Incorporated's Q1 2026 earnings call
Vertex Pharmaceuticals (NASDAQ:VRTX) reported first-quarter 2026 total revenue of $2.99 billion, up 8% year over year, as growth in its cystic fibrosis (CF) franchise and contributions from newer launches helped drive results. CEO and President Dr. Reshma Kewalramani said the company is “off to a te
Vertex Pharmaceuticals Incorporated is off to a terrific start in 2026, which we see as a year defined by execution. Q1 revenue growth was strong across the portfolio as we reach more patients with more products and delivered total product revenue of $2.99 billion, reflecting 8% growth year over year. Another highlight in Q1 was that products from the new disease areas, namely KASJEVY and GERNAVICS, drove approximately 25% of total product revenue growth.
The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
In addition to this commercialization focus, research and clinical progress remain paramount. Before I cover R&D highlights for the quarter, I would like to acknowledge our CSO, David Altshuler's retirement a year from now and the planned CSO transition to Mark Bunnage, our current SVP and Global Head of Research.
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.